Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, February 2008, p. 458-464, Vol. 52, No. 2
0066-4804/08/$08.00+0 doi:10.1128/AAC.01184-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Tammy Nachman,
Michael A. Sofia,
Peiyuan Wang,
Michael J. Otto, and
Phillip A. Furman*
Pharmasset, Inc., 303 A College Road East, Princeton, New Jersey 08540
Received 7 September 2007/ Returned for modification 12 October 2007/ Accepted 30 October 2007
β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a potent inhibitor of hepatitis C virus (HCV) RNA replication in an HCV replicon assay. The 5'-triphosphate of PSI-6130 is a competitive inhibitor of the HCV RNA-dependent RNA polymerase (RdRp) and acts as a nonobligate chain terminator. Recently, it has been shown that the metabolism of PSI-6130 also results in the formation of the 5'-triphosphate of the uridine congener, β-D-2'-deoxy-2'-fluoro-2'-C-methyluridine (PSI-6206; RO2433). Here we show that the formation of the 5'-triphosphate of RO2433 (RO2433-TP) requires the deamination of PSI-6130 monophosphate and that RO2433 monophosphate is subsequently phosphorylated to the corresponding di- and triphosphates by cellular UMP-CMP kinase and nucleoside diphosphate kinase, respectively. RO2433-TP is a potent inhibitor of the HCV RdRp; however, both enzymatic and cell-based assays show that PSI-6130 triphosphate is a more potent inhibitor of the HCV RdRp than RO2433-TP.
Published ahead of print on 12 November 2007.
Present address: RFS Pharma LLC, 1860 Montreal Road, Tucker, GA 30084.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»